Compare Bristol-Myers Squibb Co (BMY) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Microsoft — how do they compare? Bristol-Myers Squibb Co trades at $63.81 (market cap $132.45B), while Microsoft trades at $501.13 (market cap $3.76T). The key difference: Microsoft is far larger — about 28.4× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.89%). Which is the better fit depends on your goals.
| BMY | MSFT | |
|---|---|---|
Market Cap | $132.45B | $3.76T |
Sector | Health | Technology |
52-Week High | $65.89 | $542.07 |
52-Week Low | $42.60 | $352.83 |
Enterprise Value | $166.44B | $3.74T |
Dividend Yield | 3.89% | 0.72% |
Volume | — | 36,654,621 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.
BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.
Microsoft (MSFT) trades at $506.06, up 1.21% today, near its pivot point of $507. The stock shows strong bullish momentum with consistent earnings beats, including Q2 2026 EPS of $4.74 versus $4.24 expected. Revenue growth accelerated to $281.72B in 2025, with a net income margin of 40.31%. Analysts maintain an 80.49% buy rating, citing AI leadership via Azure and Copilot.
Outlook remains positive with a consensus price target of $553.70, though risks include high capital expenditures and competitive pressures in AI. The stock's valuation multiples like P/E of 28.19 are elevated, requiring sustained execution. Near-term support lies at $500, with resistance at $513.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
